Shared on19 Aug 25Fair value Increased 20%
The notable upward revision in Biovica International’s fair value reflects a sharp reduction in its future P/E ratio, with the consensus analyst price target rising from SEK1.50 to SEK1.80. What's in the News Completed SEK 80 million rights offering with A and B shares at SEK 0.63 each, including attached warrants; anchor investors subject to a 6-month lock-up post-offering.
Shared on24 Apr 25Fair value Increased 5.33%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.